Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

Also called NCT02492620

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 200 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02492620
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02492620. Randomized; no masking; primary purpose treatment. Start 2015-03 (registry gives no type); primary completion 2017-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D
Acronym
05D
Condition
Hyperphosphatemia
Condition
Iron Deficiency Anemia
Condition
Renal Insufficiency
Intervention (Drug)
Ferric Citrate
Lead sponsor
Denver Nephrologists, P.C. (class: other)
Collaborator
Keryx Biopharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct02492620
Content hash
414ef28831a2dd22c141711c331a386a435e038bba61d187227d4b4813cc257a